Blood Testing Market By Type (Clinical Chemistry, Hematology Testing, Immunology Testing, Molecular Diagnostics, Blood Gas & Electrolyte Analyzers, Urinalysis), By Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunoassay, Electrochemical Detection, Mass Spectrometry), By Application (Infectious Diseases, Cancer Detection, Cardiovascular Diseases, Diabetes Monitoring), By End-User (Hospitals, Diagnostic Laboratories, Clinics, Homecare), and By Region; Global Insights & Forecast (2023 ? 2030)

As per Intent Market Research, the Blood Testing Market was valued at USD 50.8 billion in 2024-e and will surpass USD 85.7 billion by 2030; growing at a CAGR of 9.1% during 2025 - 2030.

The blood testing market is growing rapidly due to the increasing demand for accurate diagnostic solutions, advancements in technology, and the rising prevalence of chronic diseases such as cardiovascular conditions, diabetes, and cancer. Blood testing is a critical tool in healthcare for detecting and monitoring various diseases, assessing organ function, and guiding treatment decisions. With technological innovations and improvements in testing accuracy, efficiency, and speed, blood testing is becoming an indispensable part of both clinical and homecare settings.

The market is further driven by the rise in preventive healthcare, where early detection plays a pivotal role in improving patient outcomes. With the introduction of advanced diagnostic technologies such as next-generation sequencing (NGS), polymerase chain reaction (PCR), and immunoassays, blood testing has become more accessible, precise, and capable of diagnosing a wide array of conditions. The increasing adoption of point-of-care testing and homecare solutions is also shaping the market’s growth, making blood testing more convenient and patient-centric.

Clinical Chemistry is Largest Owing to High Demand for Comprehensive Disease Diagnostics

Clinical chemistry is the largest segment in the blood testing market, owing to its widespread use in diagnosing and monitoring various diseases, including diabetes, liver disorders, and kidney diseases. Clinical chemistry tests are essential for assessing the levels of metabolites, enzymes, and electrolytes in the blood, providing critical information about a patient’s health status. These tests are commonly used in hospitals, diagnostic laboratories, and clinics, making clinical chemistry the backbone of routine blood testing.

The increasing demand for early disease detection and management of chronic conditions has significantly contributed to the growth of this segment. As clinical chemistry tests are crucial for providing detailed insights into metabolic and organ function, their importance in disease diagnosis and management continues to drive their dominance in the blood testing market.

Next-Generation Sequencing (NGS) is Fastest Growing Technology Owing to Advancements in Precision Medicine

Next-Generation Sequencing (NGS) is the fastest growing technology in the blood testing market, driven by advancements in precision medicine and the need for more accurate and comprehensive genetic testing. NGS enables the sequencing of DNA and RNA at an unprecedented scale, providing detailed genetic information that can aid in the diagnosis of genetic disorders, cancer, and other diseases. The technology allows for the detection of genetic mutations and variations, which is invaluable for personalized treatment approaches.

As the demand for personalized medicine increases, NGS is becoming an essential tool for clinicians to tailor treatments based on individual genetic profiles. The growing use of NGS for cancer detection, genetic screening, and the understanding of complex diseases is fueling its rapid adoption, positioning it as the fastest growing technology in the blood testing market.

Cancer Detection is Largest Application Owing to Increasing Cancer Incidence and Demand for Early Diagnosis

Cancer detection is the largest application in the blood testing market, driven by the increasing global incidence of cancer and the rising demand for early diagnosis and personalized treatment. Blood tests play a vital role in the early detection of various types of cancers, including breast, prostate, and colorectal cancers, by identifying biomarkers and genetic mutations associated with these diseases. The ability to detect cancer at an early stage significantly improves patient outcomes and survival rates, making cancer detection a key focus in the blood testing market.

The growing awareness of cancer and the need for regular screening, particularly among at-risk populations, is propelling the demand for blood tests that can detect cancer-related biomarkers. As research continues to uncover new biomarkers and improve diagnostic accuracy, cancer detection remains the largest and most critical application in the blood testing market.

Hospitals are Largest End-User Owing to High Volume of Diagnostic Tests and Critical Care Needs

Hospitals are the largest end-users of blood testing devices, owing to the high volume of diagnostic tests conducted in clinical settings. Blood testing is essential in hospitals for diagnosing a wide range of conditions, including infections, chronic diseases, and acute illnesses. Hospitals require rapid and accurate blood tests to provide timely diagnosis and initiate appropriate treatment plans for patients in emergency rooms, intensive care units (ICUs), and various departments.

The demand for blood testing in hospitals is fueled by the need for continuous monitoring of patient conditions and the rising prevalence of chronic diseases. With the growing complexity of healthcare, hospitals are increasingly relying on advanced blood testing technologies to improve patient care and achieve better clinical outcomes. As a result, hospitals continue to be the largest and most significant end-user of blood testing solutions.

North America is Largest Owing to Advanced Healthcare Infrastructure and High Diagnostic Testing Demand

North America is the largest region in the blood testing market, largely due to its advanced healthcare infrastructure, high demand for diagnostic testing, and strong focus on research and development. The United States, in particular, is a dominant player in the market, with its well-established healthcare systems and widespread adoption of advanced diagnostic technologies. The high prevalence of chronic diseases, such as diabetes, cancer, and cardiovascular conditions, further drives the demand for blood testing services in the region.

North America's robust healthcare framework, along with the increasing demand for early disease detection and precision medicine, ensures its position as the largest market for blood testing devices and technologies. The region’s strong focus on innovation and adoption of cutting-edge technologies, such as next-generation sequencing and PCR, continues to push the boundaries of blood testing capabilities.

Leading Companies and Competitive Landscape

The blood testing market is competitive, with key players such as Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, and Thermo Fisher Scientific leading the way. These companies offer a wide range of blood testing solutions, including clinical chemistry analyzers, hematology testing systems, molecular diagnostics, and immunoassays.

The competitive landscape is shaped by continuous innovation, with companies focusing on developing faster, more accurate, and user-friendly blood testing devices. Strategic partnerships, acquisitions, and collaborations are common as companies aim to expand their product offerings and market reach. Additionally, advancements in homecare testing and point-of-care diagnostics are expected to intensify competition in the blood testing market.

Recent Developments:

• In December 2024, Roche Diagnostics launched a new immunoassay platform. The platform enhances testing for infectious diseases with faster results.
• In November 2024, Abbott Laboratories announced a partnership to advance blood cancer diagnostics. The collaboration focuses on developing blood tests for early-stage detection.
• In October 2024, Thermo Fisher Scientific expanded its blood testing product line. The company introduced a new PCR-based test for respiratory infections.
• In September 2024, Danaher Corporation launched a next-generation hematology analyzer. This device improves the accuracy and speed of blood cell count diagnostics.
• In August 2024, Bio-Rad Laboratories unveiled a new molecular testing solution for cardiovascular diseases. This tool provides quicker, more accurate results for heart disease risk assessment.

List of Leading Companies:

• Abbott Laboratories
• Roche Diagnostics
• Siemens Healthineers
• Danaher Corporation
• Thermo Fisher Scientific
• Becton Dickinson and Company
• Bio-Rad Laboratories
• Qiagen N.V.
• Sysmex Corporation
• Ortho Clinical Diagnostics
• Hologic Inc.
• DiaSorin S.p.A.
• Beckman Coulter, Inc.
• Illumina, Inc.
• LabCorp

Report Scope: